New York State Teachers Retirement System Purchases Shares of 7,749 TransMedics Group, Inc. (NASDAQ:TMDX)

New York State Teachers Retirement System purchased a new stake in TransMedics Group, Inc. (NASDAQ:TMDX) during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 7,749 shares of the company’s stock, valued at approximately $1,217,000.

Several other hedge funds also recently added to or reduced their stakes in the business. Amalgamated Bank boosted its stake in shares of TransMedics Group by 6.7% during the 2nd quarter. Amalgamated Bank now owns 1,114 shares of the company’s stock worth $168,000 after acquiring an additional 70 shares in the last quarter. Pitcairn Co. boosted its stake in shares of TransMedics Group by 1.5% during the 1st quarter. Pitcairn Co. now owns 5,378 shares of the company’s stock worth $398,000 after acquiring an additional 78 shares in the last quarter. Harbour Capital Advisors LLC boosted its stake in shares of TransMedics Group by 1.7% during the 3rd quarter. Harbour Capital Advisors LLC now owns 4,841 shares of the company’s stock worth $760,000 after acquiring an additional 81 shares in the last quarter. Signaturefd LLC boosted its stake in shares of TransMedics Group by 26.6% during the 2nd quarter. Signaturefd LLC now owns 443 shares of the company’s stock worth $67,000 after acquiring an additional 93 shares in the last quarter. Finally, Arizona State Retirement System boosted its stake in shares of TransMedics Group by 2.1% during the 2nd quarter. Arizona State Retirement System now owns 9,158 shares of the company’s stock worth $1,379,000 after acquiring an additional 186 shares in the last quarter. 99.67% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on TMDX shares. Baird R W raised shares of TransMedics Group to a “strong-buy” rating in a research note on Tuesday, September 24th. JPMorgan Chase & Co. lowered their target price on shares of TransMedics Group from $173.00 to $116.00 and set an “overweight” rating on the stock in a research note on Tuesday, October 29th. Oppenheimer decreased their price target on shares of TransMedics Group from $200.00 to $125.00 and set an “outperform” rating on the stock in a research note on Tuesday, October 29th. Robert W. Baird decreased their price target on shares of TransMedics Group from $200.00 to $150.00 and set an “outperform” rating on the stock in a research note on Tuesday, October 29th. Finally, Canaccord Genuity Group decreased their price target on shares of TransMedics Group from $169.00 to $109.00 and set a “buy” rating on the stock in a research note on Tuesday, October 29th. One equities research analyst has rated the stock with a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $144.80.

TransMedics Group Trading Up 0.6 %

TMDX opened at $85.98 on Friday. The company has a debt-to-equity ratio of 2.42, a current ratio of 8.20 and a quick ratio of 7.33. The company’s 50 day simple moving average is $132.03 and its two-hundred day simple moving average is $139.20. TransMedics Group, Inc. has a 1-year low of $55.29 and a 1-year high of $177.37. The firm has a market capitalization of $2.89 billion, a price-to-earnings ratio of 91.47 and a beta of 2.08.

TransMedics Group (NASDAQ:TMDX) last released its earnings results on Monday, October 28th. The company reported $0.12 earnings per share for the quarter, missing analysts’ consensus estimates of $0.29 by ($0.17). TransMedics Group had a return on equity of 18.74% and a net margin of 8.14%. The business had revenue of $108.76 million during the quarter, compared to analysts’ expectations of $115.00 million. During the same period last year, the business earned ($0.12) earnings per share. The company’s revenue for the quarter was up 63.7% compared to the same quarter last year. Analysts expect that TransMedics Group, Inc. will post 1.07 EPS for the current fiscal year.

Insiders Place Their Bets

In other TransMedics Group news, insider Nicholas Corcoran sold 10,000 shares of the firm’s stock in a transaction that occurred on Tuesday, August 27th. The shares were sold at an average price of $176.02, for a total value of $1,760,200.00. Following the transaction, the insider now directly owns 21,105 shares of the company’s stock, valued at $3,714,902.10. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. In other news, insider Nicholas Corcoran sold 10,000 shares of TransMedics Group stock in a transaction that occurred on Tuesday, August 27th. The shares were sold at an average price of $176.02, for a total transaction of $1,760,200.00. Following the sale, the insider now owns 21,105 shares of the company’s stock, valued at approximately $3,714,902.10. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Tamer I. Khayal sold 2,958 shares of TransMedics Group stock in a transaction that occurred on Tuesday, October 1st. The shares were sold at an average price of $148.24, for a total transaction of $438,493.92. Following the sale, the insider now directly owns 20,843 shares in the company, valued at approximately $3,089,766.32. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 36,958 shares of company stock valued at $5,230,528 in the last ninety days. 7.00% of the stock is currently owned by corporate insiders.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.